KNSA

Business Context and Reporting Period

Kiniksa Pharmaceuticals International, Plc (KNSA) is a commercial-stage biopharmaceutical company focused on immune-modulating assets. The primary commercial product is ARCALYST (rilonacept) for recurrent pericarditis, CAPS, and DIRA. The company also has a pipeline including abiprubart (RA, Sjögren's Disease) and mavrilimumab. On June 27, 2024, the company completed a Redomiciliation, changing its jurisdiction of incorporation from Bermuda to the United Kingdom. This filing covers the quarterly period ended June 30, 2024.

Key Financial Metrics (Six Months Ended June 30, 2024)

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by 57% year-over-year (from $119.8M to $188.5M). Product revenue surged 88% (from $97.2M to $182.3M) driven by increased patient volume for ARCALYST. Conversely, License and collaboration revenue decreased 73% (from $22.7M to $6.2M) due to the timing of milestone recognitions in the prior year.
• Profitability: The company reported a net loss of $21.6M for the six months ended June 30, 2024, compared to a net income of $2.7M in the same period in 2023. This shift was primarily due to a change in income tax treatment (a provision of $9.6M in 2024 vs. a benefit of $13.3M in 2023) and increased operating expenses.
• Expense Increases:
  • Collaboration Expenses: Increased 128% (from $22.3M to $50.8M) due to the profit-sharing agreement with Regeneron as ARCALYST sales grew.
  • SG&A Expenses: Increased 39% (from $58.2M to $81.1M) driven by salesforce expansion and professional fees related to the Redomiciliation.
  • R&D Expenses: Increased 29% (from $38.9M to $50.4M), primarily due to abiprubart clinical trial activities.
• Manufacturing Transfer: The company incurred $4.9M in costs related to the technology transfer of ARCALYST manufacturing from Regeneron to Samsung Biologics.

Guidance, Outlook, and Risks

• Liquidity: Management expects cash, cash equivalents, and short-term investments ($218.8M) to fund operations for at least the next 12 months. No specific financial guidance was provided.
• Outlook: The company is advancing abiprubart (Phase 2b in Sjögren's Disease) and evaluating partnership opportunities for mavrilimumab. ARCALYST sales growth is expected to continue, though subject to reimbursement and competitive pressures.
• Key Risks:
  • Manufacturing Dependency: Reliance on third-party manufacturers (Regeneron currently, transitioning to Samsung) creates supply chain risks. The technology transfer is complex and subject to regulatory approval.
  • Redomiciliation Tax Impact: The move to the UK introduces new tax liabilities and complexities compared to the zero-tax rate in Bermuda.
  • Reimbursement: Continued commercial success depends on third-party payors maintaining favorable coverage and pricing for ARCALYST.
  • Capital Needs: The company has a history of losses and may require additional financing in the future.

Investor Verification Checklist

• Manufacturing Transition Status: Verify the timeline and regulatory progress of the ARCALYST technology transfer from Regeneron to Samsung Biologics to ensure no supply disruptions.
• ARCALYST Sales Trajectory: Monitor patient enrollment and reimbursement rates to validate the sustainability of the 88% revenue growth.
• Abiprubart Clinical Data: Review upcoming data readouts for the Phase 2b Sjögren's Disease trial and the ongoing RA trial.
• Effective Tax Rate: Assess the impact of the UK Redomiciliation on future effective tax rates and deferred tax asset valuation allowances.
• Collaboration Milestones: Track potential future milestone payments from Genentech (vixarelimab) and Huadong (rilonacept/mavrilimumab) which could impact future revenue recognition.